Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA. Issue 5 (27th January 2022)

• Record Type: Journal Article
• Authors: Zhao, Yongdong; Sullivan, Erin; Son, Mary Beth; Beukelman, Timothy
• Is Part Of: Annals of the rheumatic diseases. Volume 81:Issue 5(2022)
• Page Start: 662
• Page End: 665
• Publication Date: 2022-01-27
• Subjects: arthritis -- juvenile -- tumor necrosis factor inhibitors -- arthritis -- psoriatic; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2021-221694
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: We aimed to investigate the relationship between tumour necrosis factor inhibitors (TNFi) therapy and the onset of new psoriasis in children with juvenile idiopathic arthritis (JIA) using Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry data. Methods: De-identified data were obtained from the CARRA Registry. Patients with inflammatory bowel disease or psoriasis documented on or prior to JIA diagnosis date or with incomplete data were excluded. Exposure to TNFi was categorised as: (1) ever use; (2) current use or (3) first use only. Adjusted HRs (aHRs) were calculated between exposed and unexposed groups adjusted for methotrexate exposure, sex, race, family history of psoriasis and initial JIA category. Results: A total of 8225 patients were included with a median follow-up of 3.9 years. Over half of the patients were prescribed TNFi (n=4437, 54%). The aHR of new onset of psoriasis after ever exposure to TNFi was 2.93 (2.15 to 3.98). The incidence rate of psoriasis was the highest in children ever receiving and actively receiving adalimumab. Ever concurrent methotrexate use (HR 0.45, 0.29 to 0.69) was associated with lower risk. Conclusion: In a large prospective JIA patient registry, we observed a nearly threefold increased risk of psoriasis after TNFi exposureCite Now